Affy Claims Genotyping Market Has Slowed, But Service Providers, Rivals See No Decline in Sight | GenomeWeb

By all accounts, the past seven months have been among the most challenging Affymetrix has faced since it was founded 15 years ago.

Since August, the 1,101-employee company has faced the dual challenges of launching three major products — the Human Mapping 500K Array set for genotyping, exon arrays, and tiling arrays — and experiencing a manufacturing malfunction that forced it to revise two quarterly earnings forecasts just weeks before the company was set to report its results (see BAN 1/10/2006>, BAN 10/05/2005).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.